Company Announcement

Nykode Therapeutics to Participate in Fireside Chat at the Guggenheim 3rd Annual Healthcare Innovation Conference

Oslo, Norway, November 5, 2026 — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, today announced that its CEO, Michael Engsig, and CSO and Co-founder, Agnete Fredriksen, will participate in a fireside chat and have one-on-one meetings with investors at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference, taking place November 9–11, 2026, in Boston, Massachusetts.

Fireside Chat Details:

Event: Guggenheim 3rd Annual Healthcare Innovation Conference
Date: Tuesday, November 10, 2026
Time: 4:00 p.m. Eastern Standard Time (EST)
Host: Paul Jeng, PhD

During the discussion, management will discuss Nykode's recent progress and key value drivers, including its lead program, abi-suva, currently being evaluated in the randomized Phase 2 Abili-T trial in first-line head and neck cancer, VB10.NEO, an individualized neoantigen cancer vaccine designed to generate personalized, tumor-specific immune responses, and its immune tolerance platform.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidate is abi-suva, a cancer vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027. VB10.NEO, an individualized cancer neoantigen cancer vaccine, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway